Conmind Medical Closes RMB 100 Million Series B Financing

August 21, 2023 China, Financing

China Shenzhen-based Conmind Medical announces the completion of nearly RMB 100 million ($13.7 million) series B financing led by Turing Private Equity, Zhuhai High-Tech Investment, Chengdu Chuanghe Ruixin, and Triwise Capital, for the development and commercialization of cardiovascular devices.

Founded in 2020, Conmind Medical focuses on innovative interventional products in the cardiac, cerebrovascular and pan-vascular fields. The company’s neurointerventional product pipeline focuses on holistic solutions for the treatment of aneurysms, while its cardiac interventional products are heavily involved in interventional repair of mitral and tricuspid valves. The main products include the Campsis™ microcatheter, Thatch™ micro guidewire, Cycas™ embolic protection system, Crassula™ intracranial coil embolization system, Fringe® support catheter and HaloChord® transcatheter mitral valve chordal repair.

In response to the many clinical shortcomings of imported products, Conmind Medical has independently developed a series of high-quality innovative devices that are more in line with domestic clinical needs and doctors’ surgical habits, said Hui Huang, co-founder of Conmind Medical. In the next three years, the company will launch 3 to 5 innovative products to further increase the market share of domestic interventional devices, he added.

The Post is Available in: English – 简体中文